Edna GrÃ¼nblatt

List of Publications by Year
in descending order

193 papers	11,014 citations	41344 49 h-index	38395 95 g-index
206 all docs	206 docs citations	206 times ranked	16264 citing authors

#	Article	IF	Citations
1	An overview of the first 5â€‰years of the ENIGMA obsessiveâ€“compulsive disorder working group: The power of worldwide collaboration. Human Brain Mapping, 2022, 43, 23-36.	3.6	51
2	Problematic use of the internet during the COVID-19 pandemic: Good practices and mental health recommendations. Comprehensive Psychiatry, 2022, 112, 152279.	3.1	52
3	Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Doubleâ€Blind, Placeboâ€Controlled, Crossover Study in Healthy Subjects. Clinical Pharmacology and Therapeutics, 2022, 111, 886-895.	4.7	70
4	Media use and emotional distress under COVID-19 lockdown in a clinical sample referred for internalizing disorders: A Swiss adolescents' perspective. Journal of Psychiatric Research, 2022, 147, 313-323.	3.1	7
5	New insights into the genetic etiology of Alzheimerâ€™s disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
6	Brain-derived neurotrophic factor protects serotonergic neurons against 3,4-methylenedioxymethamphetamine (â€œEcstasyâ€) induced cytoskeletal damage. Journal of Neural Transmission, 2022, 129, 703-711.	2.8	5
7	Promising Developments in the Use of Induced Pluripotent Stem Cells in Research of ADHD. Current Topics in Behavioral Neurosciences, 2022, , .	1.7	1
8	Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	9.0	31
9	A review of the genetic basis of problematic Internet use. Current Opinion in Behavioral Sciences, 2022, 46, 101149.	3.9	9
10	Genetics of OCD and Related Disorders; Searching for Shared Factors. Current Topics in Behavioral Neurosciences, 2021, 49, 1-16.	1.7	6
11	Genome-wide association study of pediatric obsessive-compulsive traits: shared genetic risk between traits and disorder. Translational Psychiatry, 2021, 11, 91.	4.8	23
12	The Interplay Between Postsynaptic Striatal D2/3 Receptor Availability, Adversity Exposure and Odd Beliefs: A [11C]-Raclopride PET Study. Schizophrenia Bulletin, 2021, 47, 1495-1508.	4.3	3
13	Generation of integration-free induced pluripotent stem cell lines from four pediatric ADHD patients. Stem Cell Research, 2021, 53, 102268.	0.7	7
14	Generation of integration-free induced pluripotent stem cells from healthy individuals. Stem Cell Research, 2021, 53, 102269.	0.7	6
15	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	12.8	140
16	Media use before, during and after COVID-19 lockdown according to parents in a clinically referred sample in child and adolescent psychiatry: Results of an online survey in Switzerland. Comprehensive Psychiatry, 2021, 109, 152260.	3.1	27
17	Polygenic risk scores across the extended psychosis spectrum. Translational Psychiatry, 2021, 11, 600.	4.8	11
18	P.0006 BDNF levels in blood serum and plasma of MDMA users and MDMA-naÃ¯ve controls. European Neuropsychopharmacology, 2021, 53, S4-S5.	0.7	0

#	Article	IF	Citations
19	P.0025 Preliminary results of growth rate profiling of induced pluripotent stem cells and neuronal progenitor cells from Attention-Deficit Hyperactivity Disorder. European Neuropsychopharmacology, 2021, 53, S19-S20.	0.7	0
20	Genetics of obsessive-compulsive disorder and Tourette disorder. , 2020, , 239-252.		1
21	Epigenetic mechanisms in schizophrenia and other psychotic disorders: a systematic review of empirical human findings. Molecular Psychiatry, 2020, 25, 1718-1748.	7.9	97
22	High-resolution chromosomal microarrayÂanalysis for copy-number variations in high-functioning autism reveals large aberration typical for intellectual disability. Journal of Neural Transmission, 2020, 127, 81-94.	2.8	5
23	Psychiatric symptoms and expression of glucocorticoid receptor gene in cocaine users: A longitudinal study. Journal of Psychiatric Research, 2020, 121, 126-134.	3.1	5
24	Rare copy number variants in individuals at clinical high risk for psychosis: Enrichment of synaptic/brainâ€related functional pathways. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2020, 183, 140-151.	1.7	0
25	The stressâ€“Wnt-signaling axis: a hypothesis for attention-deficit hyperactivity disorder and therapy approaches. Translational Psychiatry, 2020, 10, 315.	4.8	20
26	Preventing problematic internet use during the COVID-19 pandemic: Consensus guidance. Comprehensive Psychiatry, 2020, 100, 152180.	3.1	522
27	Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders. International Clinical Psychopharmacology, 2020, 35, 173-193.	1.7	70
28	ADHD: Current Concepts and Treatments in Children and Adolescents. Neuropediatrics, 2020, 51, 315-335.	0.6	117
29	Profiling parvalbumin interneurons using iPSC: challenges and perspectives for Autism Spectrum Disorder (ASD). Molecular Autism, 2020, 11, 10.	4.9	10
30	Glucocorticoid receptor gene variants and lower expression of NR3C1 are associated with cocaine use. Addiction Biology, 2019, 24, 730-742.	2.6	23
31	No Association of Variants of the NPY-System With Obsessive-Compulsive Disorder in Children and Adolescents. Frontiers in Molecular Neuroscience, 2019, 12, 112.	2.9	1
32	Guidelines for the standardized collection of blood-based biomarkers in psychiatry: Steps for laboratory validity â€“ a consensus of the Biomarkers Task Force from the WFSBP. World Journal of Biological Psychiatry, 2019, 20, 340-351.	2.6	20
33	Association study and a systematic meta-analysis of the VNTR polymorphism in the 3â€²-UTR of dopamine transporter gene and attention-deficit hyperactivity disorder. Journal of Neural Transmission, 2019, 126, 517-529.	2.8	24
34	Influence of oxytocin receptor single nucleotide sequence variants on contractility of human myometrium: an in vitro functional study. BMC Medical Genetics, 2019, 20, 178.	2.1	12
35	New insights and perspectives on the genetics of obsessive-compulsive disorder. Psychiatric Genetics, 2019, 29, 142-151.	1.1	16
36	Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. Cell, 2019, 179, 1469-1482.e11.	28.9	935

#	Article	IF	Citations
37	Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice. Neuropharmacology, 2019, 148, 50-67.	4.1	17
38	Astrocyte- and Microglia-Specific Mitochondrial DNA Deletions Levels in Sporadic Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2019, 67, 149-157.	2.6	12
39	The involvement of the canonical Wntâ€signaling receptor LRP5 and LRP6 gene variants with ADHD and sexual dimorphism: Association study and metaâ€analysis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2019, 180, 365-376.	1.7	16
40	Methylphenidate enhances neuronal differentiation and reduces proliferation concomitant to activation of Wnt signal transduction pathways. Translational Psychiatry, 2018, 8, 51.	4.8	21
41	Differential Alterations in Metabolism and Proteolysis-Related Proteins in Human Parkinsonâ€™s Disease Substantia Nigra. Neurotoxicity Research, 2018, 33, 560-568.	2.7	31
42	Emerging role of miRNA in attention deficit hyperactivity disorder: a systematic review. ADHD Attention Deficit and Hyperactivity Disorders, 2018, 10, 49-63.	1.7	39
43	Combining genetic and epigenetic parameters of the serotonin transporter gene in obsessive-compulsive disorder. Journal of Psychiatric Research, 2018, 96, 209-217.	3.1	43
44	Effects of oxytocin and arginine vasopressin on the proliferation and differentiation of a serotonergic cell line. Journal of Neural Transmission, 2018, 125, 103-106.	2.8	2
45	Explorative results from multistep screening for potential genetic risk loci of Alzheimerâ€™s disease in the longitudinal VITA study cohort. Journal of Neural Transmission, 2018, 125, 77-87.	2.8	8
46	Revealing the complex genetic architecture of obsessiveâ€“compulsive disorder using meta-analysis. Molecular Psychiatry, 2018, 23, 1181-1188.	7.9	400
47	Manifesto for a European research network into Problematic Usage of the Internet. European Neuropsychopharmacology, 2018, 28, 1232-1246.	0.7	216
48	Improved Generation of Induced Pluripotent Stem Cells From Hair Derived Keratinocytes â€“ A Tool to Study Neurodevelopmental Disorders as ADHD. Frontiers in Cellular Neuroscience, 2018, 12, 321.	3.7	22
49	Neurochemical markers as potential indicators of postmortem tissue quality. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 150, 119-127.	1.8	4
50	Neuregulin 1 (NRG1) gene expression predicts functional outcomes in individuals at clinical high-risk for psychosis. Psychiatry Research, 2018, 266, 143-146.	3.3	4
51	A systematic meta-analysis of the association of Neuregulin 1 (NRG1), d-amino acid oxidase (DAO), and DAO activator (DAOA)/G72 polymorphisms with schizophrenia. Journal of Neural Transmission, 2018, 125, 89-102.	2.8	21
52	Î±_{2A}â€Adrenergic receptor polymorphisms and mRNA expression levels are associated with delay discounting in cocaine users. Addiction Biology, 2017, 22, 561-569.	2.6	14
53	Simultaneous determination of MAO-A and -B activity following first time intake of an irreversible MAO-B inhibitor in patients with Parkinsonâ€™s disease. Journal of Neural Transmission, 2017, 124, 745-748.	2.8	8
54	The hallucinogen 2,5-dimethoxy-4-iodoamphetamine hydrochloride activates neurotrophin receptors in a neuronal cell line and promotes neurites extension. Journal of Neural Transmission, 2017, 124, 749-759.	2.8	8

#	Article	IF	Citations
55	Integrating evolutionary and regulatory information with a multispecies approach implicates genes and pathways in obsessive-compulsive disorder. Nature Communications, 2017, 8, 774.	12.8	52
56	The impact of methylphenidate and its enantiomers on dopamine synthesis and metabolism in vitro. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 79, 281-288.	4.8	12
57	The diabetic brain and cognition. Journal of Neural Transmission, 2017, 124, 1431-1454.	2.8	77
58	Determination of Monoamine Oxidase A and B Activity in Long-Term Treated Patients With Parkinson Disease. Clinical Neuropharmacology, 2017, 40, 208-211.	0.7	20
59	DNA methylation profiles of elderly individuals subjected to indentured childhood labor and trauma. BMC Medical Genetics, 2017, 18, 21.	2.1	27
60	Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms. World Journal of Biological Psychiatry, 2017, 18, 330-356.	2.6	33
61	Biological markers for anxiety disorders, OCD and PTSD: A consensus statement. Part II: Neurochemistry, neurophysiology and neurocognition. World Journal of Biological Psychiatry, 2017, 18, 162-214.	2.6	226
62	A Single Dose of LSD Does Not Alter Gene Expression of the Serotonin 2A Receptor Gene (HTR2A) or Early Growth Response Genes (EGR1-3) in Healthy Subjects. Frontiers in Pharmacology, 2017, 8, 423.	3.5	11
63	Prediction Analysis for Transition to Schizophrenia in Individuals at Clinical High Risk for Psychosis: The Relationship of DAO, DAOA, and NRG1 Variants with Negative Symptoms and Cognitive Deficits. Frontiers in Psychiatry, 2017, 8, 292.	2.6	16
64	Expression of D-Amino Acid Oxidase (DAO/DAAO) and D-Amino Acid Oxidase Activator (DAOA/G72) during Development and Aging in the Human Post-mortem Brain. Frontiers in Neuroanatomy, 2017, 11, 31.	1.7	31
65	Controversial Effects of D-Amino Acid Oxidase Activator (DAOA)/G72 on D-Amino Acid Oxidase (DAO) Activity in Human Neuronal, Astrocyte and Kidney Cell Lines: The N-methyl D-aspartate (NMDA) Receptor Hypofunction Point of View. Frontiers in Molecular Neuroscience, 2017, 10, 342.	2.9	10
66	High resolution chromosomal microarray analysis in paediatric obsessive-compulsive disorder. BMC Medical Genomics, 2017, 10, 68.	1.5	21
67	A pilot investigation on DNA methylation modifications associated with complex posttraumatic symptoms in elderly traumatized in childhood. BMC Research Notes, 2017, 10, 752.	1.4	7
68	Aldehyde dehydrogenase (ALDH) in Alzheimerâ€™s and Parkinsonâ€™s disease. Journal of Neural Transmission, 2016, 123, 83-90.	2.8	66
69	Biological markers for anxiety disorders, OCD and PTSD â€“ a consensus statement. Part I: Neuroimaging and genetics. World Journal of Biological Psychiatry, 2016, 17, 321-365.	2.6	118
70	CNTNAP2 gene in high functioning autism: no association according to family and meta-analysis approaches. Journal of Neural Transmission, 2016, 123, 353-363.	2.8	16
71	Serotonin Transporter and Tryptophan Hydroxylase Gene Variations Mediate Working Memory Deficits of Cocaine Users. Neuropsychopharmacology, 2015, 40, 2929-2937.	5.4	16
72	Cross-Disorder Genome-Wide Analyses Suggest a Complex Genetic Relationship Between Tourette's Syndrome and OCD. American Journal of Psychiatry, 2015, 172, 82-93.	7.2	117

#	Article	IF	Citations
73	Nine-month follow-up of the insulin receptor signalling cascade in the brain of streptozotocin rat model of sporadic Alzheimerâ€™s disease. Journal of Neural Transmission, 2015, 122, 565-576.	2.8	41
74	Changes in the expression of genes related to neuroinflammation over the course of sporadic Alzheimerâ€™s disease progression: CX3CL1, TREM2, and PPARÎ³. Journal of Neural Transmission, 2015, 122, 1069-1076.	2.8	43
75	Neurotrophin blood-based gene expression and social cognition analysis in patients with autism spectrum disorder. Neurogenetics, 2015, 16, 123-131.	1.4	35
76	Regionâ€specific regulation of the serotonin 2<scp>A</scp> receptor expression in development and ageing in post mortem human brain. Neuropathology and Applied Neurobiology, 2015, 41, 520-532.	3.2	11
77	Characterization of cognitive deficits in spontaneously hypertensive rats, accompanied by brain insulin receptor dysfunction. Journal of Molecular Psychiatry, 2015, 3, 6.	2.0	23
78	Common mechanisms in neurodegeneration and neuroinflammation: a BrainNet Europe gene expression microarray study. Journal of Neural Transmission, 2015, 122, 1055-1068.	2.8	126
79	Extraordinarily Fast Response to Low-Dose Sertraline in a Child with Severe Obsessive-Compulsive Disorder and High Functioning Serotonin Transporter Genotype. Journal of Child and Adolescent Psychopharmacology, 2014, 24, 102-104.	1.3	4
80	Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene. Molecular Autism, 2014, 5, 43.	4.9	59
81	Imaging genetics in obsessive-compulsive disorder: Linking genetic variations to alterations in neuroimaging. Progress in Neurobiology, 2014, 121, 114-124.	5.7	34
82	Altered peripheral BDNF mRNA expression and BDNF protein concentrations in blood of children and adolescents with autism spectrum disorder. Journal of Neural Transmission, 2014, 121, 1117-1128.	2.8	47
83	Association study in siblings and case-controls of serotonin- and oxytocin-related genes with high functioning autism. Journal of Molecular Psychiatry, 2014, 2, 1.	2.0	39
84	Investigation of association of serotonin transporter and monoamine oxidaseâ€A genes with Alzheimer's disease and depression in the VITA study cohort: A 90â€month longitudinal study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2014, 165, 184-191.	1.7	12
85	Chronic monoamine oxidase-B inhibitor treatment blocks monoamine oxidase-A enzyme activity. Journal of Neural Transmission, 2014, 121, 379-383.	2.8	29
86	P.1.g.071 Interaction between serotonin 1A and 2A receptor subtypes in neuronal and lymphoblastoid cells. European Neuropsychopharmacology, 2014, 24, S244-S245.	0.7	0
87	Copy Number Variation in Obsessive-Compulsive Disorder and Tourette Syndrome: A Cross-Disorder Study. Journal of the American Academy of Child and Adolescent Psychiatry, 2014, 53, 910-919.	0.5	111
88	Trio study and meta-analysis support the association of genetic variation at the serotonin transporter with early-onset obsessiveâ€“compulsive disorder. Neuroscience Letters, 2014, 580, 100-103.	2.1	39
89	The neurobiological link between OCD and ADHD. ADHD Attention Deficit and Hyperactivity Disorders, 2014, 6, 175-202.	1.7	73
90	Prenatal stress increases the striatal and hippocampal expression of correlating câ€FOS and serotonin transporters in murine offspring. International Journal of Developmental Neuroscience, 2014, 38, 30-35.	1.6	22

#	Article	IF	Citations
91	Aldehyde dehydrogenase 2 in sporadic Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, S68-S72.	2.2	26
92	Enhancement of cell viability after treatment with polyunsaturated fatty acids. Neuroscience Letters, 2014, 559, 56-60.	2.1	10
93	Neuron-Specific Alterations in Signal Transduction Pathways associated with Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 40, 135-142.	2.6	29
94	Real-Time Impedance-based Cell Analyzer as a Tool to Delineate Molecular Pathways Involved in Neurotoxicity and Neuroprotection in a Neuronal Cell Line. Journal of Visualized Experiments, 2014, , e51748.	0.3	2
95	Wie biologisch sind ZwangsstÃ¶rungen?. Kindheit Und Entwicklung (discontinued), 2014, 23, 75-85.	0.4	5
96	Methylphenidate enhances neural stem cell differentiation. Journal of Molecular Psychiatry, 2013, 1, 5.	2.0	9
97	Is the treatment with psychostimulants in children and adolescents with attention deficit hyperactivity disorder harmful for the dopaminergic system?. ADHD Attention Deficit and Hyperactivity Disorders, 2013, 5, 71-81.	1.7	17
98	Manifesto for a European research network into obsessive-compulsive and related disorders. European Neuropsychopharmacology, 2013, 23, 561-568.	0.7	28
99	In vitro study methodologies to investigate genetic aspects and effects of drugs used in attention-deficit hyperactivity disorder. Journal of Neural Transmission, 2013, 120, 131-139.	2.8	8
100	Different effects of soluble and aggregated amyloid Î²42 on gene/protein expression and enzyme activity involved in insulin and APP pathways. Journal of Neural Transmission, 2013, 120, 113-120.	2.8	15
101	Editorial. Journal of Neural Transmission, 2013, 120, 1-2.	2.8	2
102	5-HT2A serotonin receptor agonist DOI alleviates cytotoxicity in neuroblastoma cells: Role of the ERK pathway. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 44, 64-72.	4.8	16
103	Alzheimer's disease and type 2 diabetes: Two diseases, one common link?. World Journal of Biological Psychiatry, 2013, 14, 233-240.	2.6	16
104	The Loudness Dependence of Auditory Evoked Potentials (LDAEP) as an Indicator of Serotonergic Dysfunction in Patients with Predominant Schizophrenic Negative Symptoms. PLoS ONE, 2013, 8, e68650.	2.5	27
105	Neuron-Specific Mitochondrial DNA Deletion Levels in Sporadic AlzheimerÂ´s Disease. Current Alzheimer Research, 2013, 10, 1041-1046.	1.4	14
106	Selection of novel reference genes for use in the human central nervous system: a BrainNet Europe Study. Acta Neuropathologica, 2012, 124, 893-903.	7.7	110
107	Parkinson's disease: Molecular risk factors. Parkinsonism and Related Disorders, 2012, 18, S45-S48.	2.2	14
108	1.12.1 PARKINSON'S DISEASE: MOLECULAR RISK FACTORS. Parkinsonism and Related Disorders, 2012, 18, S5.	2.2	0

#	Article	IF	Citations
109	S.08.01 Potential biomarkers and genetic findings in ADHD. European Neuropsychopharmacology, 2012, 22, S123-S124.	0.7	0
110	S.08.03 New findings of copy number variations in OCD. European Neuropsychopharmacology, 2012, 22, S124.	0.7	0
111	Inflammatory Pathways in Parkinsonâ€™s Disease; A BNE Microarray Study. Parkinson's Disease, 2012, 2012, 1-16.	1.1	51
112	A molecular signature in blood identifies early Parkinsonâ€™s disease. Molecular Neurodegeneration, 2012, 7, 26.	10.8	99
113	Pilot study: potential transcription markers for adult attention-deficit hyperactivity disorder in whole blood. ADHD Attention Deficit and Hyperactivity Disorders, 2012, 4, 77-84.	1.7	7
114	Pilot study on HTR2A promoter polymorphism, â^'1438G/A (rs6311) and a nearby copy number variation showed association with onset and severity in early onset obsessiveâ€“compulsive disorder. Journal of Neural Transmission, 2012, 119, 507-515.	2.8	32
115	Altered mRNA expression of monoaminergic candidate genes in the blood of children with attention deficit hyperactivity disorder and autism spectrum disorder. World Journal of Biological Psychiatry, 2011, 12, 104-108.	2.6	27
116	Association of a Functional NOS1 Promoter Repeat with Alzheimer's Disease in the VITA Cohort. Journal of Alzheimer's Disease, 2011, 23, 327-333.	2.6	16
117	Genetic variation in the choline O-acetyltransferase gene in depression and Alzheimerâ€™s disease: The VITA and Milano studies. Journal of Psychiatric Research, 2011, 45, 1250-1256.	3.1	15
118	Methyl- and acetyltransferases are stable epigenetic markers postmortem. Cell and Tissue Banking, 2011, 12, 289-297.	1.1	12
119	The link between iron, metabolic syndrome, and Alzheimerâ€™s disease. Journal of Neural Transmission, 2011, 118, 371-379.	2.8	50
120	Transcriptional alterations under continuous or pulsatile dopaminergic treatment in dyskinetic rats. Journal of Neural Transmission, 2011, 118, 1717-1725.	2.8	7
121	Editorial. Journal of Neural Transmission, 2011, 118, 299-300.	2.8	3
122	Diabetes Type II: A Risk Factor for Depressionâ€“Parkinsonâ€“Alzheimer?. Neurotoxicity Research, 2011, 19, 253-265.	2.7	50
123	Disorder-specific effects of polymorphisms at opposing ends of the Insulin Degrading Enzymegene. BMC Medical Genetics, 2011, 12, 151.	2.1	10
124	Alteration of the pro-oxidant xanthine oxidase (XO) in the thalamus and occipital cortex of patients with schizophrenia. World Journal of Biological Psychiatry, 2011, 12, 588-597.	2.6	27
125	d/l threo-methylphenidate enantiomers influence on catecholaminergic enzyme activities. Pharmacopsychiatry, 2011, 44, .	3.3	0
126	Genetics of early-onset obsessiveâ€“compulsive disorder. European Child and Adolescent Psychiatry, 2010, 19, 227-235.	4.7	329

#	Article	IF	Citations
127	Pilot study: peripheral biomarkers for diagnosing sporadic Parkinsonâ€™s disease. Journal of Neural Transmission, 2010, 117, 1387-1393.	2.8	57
128	Effects of methylphenidate: the cellular point of view. ADHD Attention Deficit and Hyperactivity Disorders, 2010, 2, 225-232.	1.7	29
129	Increased Mitochondrial Aldehydedehydrogenase in the putamen of individuals with Alzheimer's disease. Journal of Alzheimer's Disease, 2010, 19, 1295-1301.	2.6	34
130	Increased xanthine oxidase in the thalamus and putamen in depression. World Journal of Biological Psychiatry, 2010, 11, 314-320.	2.6	72
131	Can enzyme kinetics of prooxidants teach us a lesson about the treatment of Alzheimer's disease: A pilot post-mortem study. World Journal of Biological Psychiatry, 2010, 11, 677-681.	2.6	5
132	Chronic exogenous corticosterone administration generates an insulin-resistant brain state in rats. Stress, 2010, 13, 123-131.	1.8	23
133	Brain tryptophan rather than pH-value is altered as consequence of artificial postmortem interval and storage conditions. Neurochemistry International, 2010, 57, 819-822.	3.8	7
134	PGC-1 Î±, A Potential Therapeutic Target for Early Intervention in Parkinsonâ€™s Disease. Science Translational Medicine, 2010, 2, 52ra73.	12.4	691
135	Trabalho de consenso de forÃ§a-tarefa da WFSBP sobre marcadores biolÃ³gicos das demÃªncias: contribuiÃ§Ã£o da anÃ¡lise do LCR e do sangue para o diagnÃ³stico precoce e diferencial das demÃªncias. Revista De Psiquiatria Clinica, 2009, 36, 1-16.	0.6	1
136	Modeling Sporadic Alzheimer's Disease: The Insulin Resistant Brain State Generates Multiple Long-Term Morphobiological Abnormalities Including Hyperphosphorylated Tau Protein and Amyloid-Î². Journal of Alzheimer's Disease, 2009, 18, 729-750.	2.6	94
137	Genetic risk factors and markers for Alzheimerâ€™s disease and/or depression in the VITA study. Journal of Psychiatric Research, 2009, 43, 298-308.	3.1	54
138	pH measurement as quality control on human post mortem brain tissue: a study of the BrainNet Europe consortium. Neuropathology and Applied Neurobiology, 2009, 35, 329-337.	3.2	93
139	Tryptophan is a marker of human postmortem brain tissue quality. Journal of Neurochemistry, 2009, 110, 1400-1408.	3.9	13
140	Gene Expression as Peripheral Biomarkers for Sporadic Alzheimer's Disease. Journal of Alzheimer's Disease, 2009, 16, 627-634.	2.6	57
141	Schizophrenia: From the brain to peripheral markers. A consensus paper of the WFSBP task force on biological markers. World Journal of Biological Psychiatry, 2009, 10, 127-155.	2.6	64
142	Stress and methylphenidate treatment, both modulate neuronal activity in an animal model for ADHD. Pharmacopsychiatry, 2009, 42, .	3.3	0
143	Continuous versus pulsatile administration of rotigotine in 6-OHDA-lesioned rats: contralateral rotations and abnormal involuntary movements. Journal of Neural Transmission, 2008, 115, 1385-1392.	2.8	33
144	Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. Journal of Neurochemistry, 2008, 77, 146-156.	3.9	6

#	Article	IF	Citations
145	Genomic aspects of sporadic Parkinson's disease. Parkinsonism and Related Disorders, 2008, 14, S88-S91.	2.2	3
146	Altered glial cell line-derived neurotrophic factor (GDNF) concentrations in the brain of patients with depressive disorder: A comparative post-mortem study. European Psychiatry, 2008, 23, 413-420.	0.2	68
147	Commonalities in the genetics of Alzheimerâ€™s disease and Parkinsonâ€™s disease. Expert Review of Neurotherapeutics, 2008, 8, 1865-1877.	2.8	13
148	Genes and Oxidative Stress in Sporadic and Familial Parkinsonism: cDNA Microarray Studies. , 2007, , 201-218.		0
149	Alterations in Expression of Glutamatergic Transporters and Receptors in Sporadic Alzheimer's Disease. Journal of Alzheimer's Disease, 2007, 11, 97-116.	2.6	257
150	Comparison Analysis of Gene Expression Patterns between Sporadic Alzheimer's and Parkinson's Disease. Journal of Alzheimer's Disease, 2007, 12, 291-311.	2.6	57
151	1.011 Early diagnosis for Parkinson's disease according to whole blood gene profile. Parkinsonism and Related Disorders, 2007, 13, S30.	2.2	0
152	1.100 Early diagnosis for Parkinson's disease according to whole blood gene profile. Parkinsonism and Related Disorders, 2007, 13, S33-S34.	2.2	0
153	Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. Journal of Neurochemistry, 2007, 101, 757-770.	3.9	321
154	Behavioural and expressional phenotyping of nitric oxide synthase-I knockdown animals. , 2007, , 69-85.		40
155	The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice. Journal of Neural Transmission, 2007, 114, 205-209.	2.8	27
156	Biostatistical analysis of gene microarrays reveals diverse expression clusters between macaque subspecies in brain SIV infection. , 2007, , 317-322.		0
157	Gene and Protein Expression Profiling in Parkinson's Disease: Quest for Neuroprotective Drugs. , 2007, , 61-76.		0
158	HIV Dementia: A Neurodegenerative Disorder with Viral Etiology. , 2007, , 359-371.		0
159	Methylphenidate effects on cell growth and maturation in neuronal stem cells. Pharmacopsychiatry, 2007, 40, .	3.3	0
160	Gene expression alterations in brain areas of intracerebroventricular streptozotocin treated rat. Journal of Alzheimer's Disease, 2006, 9, 261-271.	2.6	33
161	Estrogen Receptor Î² Gene (ESRÎ²) 3â€²-UTR Variants in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2006, 20, 322-323.	1.3	16
162	Serotonin transporter polymorphism and LDL-cholesterol. Molecular Psychiatry, 2006, 11, 707-709.	7.9	24

#	Article	IF	Citations
163	Microarray analysis reveals distinct gene expression patterns in the mouse cortex following chronic neuroleptic and stimulant treatment: implications for body weight changes. Journal of Neural Transmission, 2006, 113, 1383-1393.	2.8	23
164	Association study of BDNF and CNTF polymorphism to depression in non-demented subjects of the â€œVITAâ€•study. Journal of Affective Disorders, 2006, 96, 111-116.	4.1	22
165	Association Study of the 5-HTTLPR Polymorphism and Depression in 75-Year-Old Nondemented Subjects From the Vienna Transdanube Aging (VITA) Study. Journal of Clinical Psychiatry, 2006, 67, 1373-1378.	2.2	34
166	Early impairment in dopaminergic neurotransmission in brains of SIV-infected rhesus monkeys due to microglia activation. Journal of Neurochemistry, 2005, 95, 377-387.	3.9	51
167	Consensus Paper of the WFSBP Task Force on Biological Markers of Dementia: The role of CSF and blood analysis in the early and differential diagnosis of dementia. World Journal of Biological Psychiatry, 2005, 6, 69-84.	2.6	105
168	Oxidative stress related markers in the â€œVITAâ€•and the centenarian projects. Neurobiology of Aging, 2005, 26, 429-438.	3.1	34
169	Gene Expression Profiling of Sporadic Parkinson's Disease Substantia Nigra Pars Compacta Reveals Impairment of Ubiquitinâ€Proteasome Subunits, SKP1A, Aldehyde Dehydrogenase, and Chaperone HSCâ€70. Annals of the New York Academy of Sciences, 2005, 1053, 356-375.	3.8	2
170	Gene Expression Profiling of Sporadic Parkinson's Disease Substantia Nigra Pars Compacta Reveals Impairment of Ubiquitin-Proteasome Subunits, SKP1A, Aldehyde Dehydrogenase, and Chaperone HSC-70. Annals of the New York Academy of Sciences, 2005, 1053, 356-375.	3.8	136
171	Gene expression profile in streptozotocin rat model for sporadic Alzheimer?s disease. Journal of Neural Transmission, 2004, 111, 367-386.	2.8	48
172	Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. Journal of Neural Transmission, 2004, 111, 1543-1573.	2.8	326
173	Monoamine Oxidase-B Inhibition in Alzheimer's Disease. NeuroToxicology, 2004, 25, 271-277.	3.0	221
174	The benefits of microarrays as tools for studying neuropsychiatric disorders. Drugs of Today, 2004, 40, 147.	2.4	10
175	The benefits of microarrays as tools for studying neuropsychiatric disorders. Drugs of Today, 2004, 40, 147-56.	1.1	5
176	Neuroprotective Strategies in Parkinson???s Disease. CNS Drugs, 2003, 17, 729-762.	5.9	206
177	Genes and oxidative stress in parkinsonism: cDNA microarray studies. Advances in Neurology, 2003, 91, 123-32.	0.8	13
178	Preclinical versus clinical neuroprotection. Advances in Neurology, 2003, 91, 309-28.	0.8	0
179	Free radicals in Parkinson's disease. Journal of Neurology, 2002, 249, 1-1.	3.6	95
180	Early and late gene changes in MPTP mice model of Parkinson's disease employing cDNA microarray. Neurochemical Research, 2002, 27, 1231-1243.	3.3	58

#	Article	IF	Citations
181	Early and late molecular events in neurodegeneration and neuroprotection in Parkinsonâ€™s disease MPTP model as assessed by cDNA microarray; the role of iron. Neurotoxicity Research, 2002, 4, 679-689.	2.7	33
182	Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. Journal of Neurochemistry, 2001, 78, 1-12.	3.9	189
183	Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss. Journal of Neurochemistry, 2001, 77, 146-156.	3.9	86
184	Drugs to prevent cell death in Parkinson's disease. Neuroprotection against oxidative stress and inflammatory gene expression. Advances in Neurology, 2001, 86, 115-24.	0.8	7
185	Neuroprotective Strategies in Parkinson's Disease Using the Models of 6â€Hydroxydopamine and MPTP^a. Annals of the New York Academy of Sciences, 2000, 899, 262-273.	3.8	78
186	Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine. , 2000, , 83-96.		14
187	cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinsonâ€™s disease. , 2000, , 117-124.		32
188	MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinsonâ€™s disease: neuroprotective strategies. Journal of Neurology, 2000, 247, II95-II102.	3.6	78
189	Contribution of Intracellular Non-Haem Iron, NF-kB Activation and Inflammatory Responses to Neurodegeneration in Parkinsonâ€™s Disease: Prospects for Neuroprotection. , 2000, , 277-288.		0
190	The Pivotal Role of Iron in NF-kappaB Activation and Nigrostriatal Dopaminergic Neurodegeneration: Prospects for Neuroprotection in Parkinson's Disease with Iron Chelators. Annals of the New York Academy of Sciences, 1999, 890, 7-25.	3.8	81
191	Apomorphine protects against MPTP-induced neurotoxicity in mice. Movement Disorders, 1999, 14, 612-618.	3.9	114
192	Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity. , 1999, 55, 57-70.		25
193	Increased xanthine oxidase in the thalamus and putamen in depression. World Journal of Biological Psychiatry, 0, , 1-7.	2.6	15